Search & Analyze

Sai Life Sciences Ltd.

HealthcarePharmaceuticals & Drugs

www.sailife.com BSE: 544306NSE: SAILIFE

₹1,395.00BSE0.07%

23 Oct, 4:01 PM

₹1,395.00

₹29.65K Cr

81.97

11.61

15.16%

₹1,429.40

₹1,384.10

₹1,697.00

₹786.15

Customise metrics bar

Sai Life Sciences Ltd. (SAILIFE) share price closed at ₹1,395.00 on the BSE on Friday, October 23, 2026, down by 0.07% from its of ₹1,396.00. In that session SAILIFE reached a of 1,429.40 and of 1,384.10. The for the session was 1,402.50. The stands at 1,509.74 and is at 1,181.80. Looking at , the stock ended the session in Downtrend.

Stock Overview

Symbol

SAILIFE

₹1,392.25

₹1,396.00

₹1,402.50

₹1,509.74

Price 7.60% below

₹1,181.80

Price 18.04% above

24.06% of range

₹1,384.10₹1,429.40

66.84% of range

₹786.15₹1,697.00

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,743.00	34.58	4,18,204.09	0.92	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	8,984.00	81.54	2,38,496.97	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,482.00	80.26	1,70,480.87	0.85	534.00	-9.64%	4,979.00	50.79%	19.27
ZYDUSLIFE ZYDUSLIFE	1,127.85	24.93	1,12,503.47	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,337.00	32.04	1,08,012.30	0.97	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,974.00	97.55	1,06,657.63	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,224.50	36.50	1,02,206.60	0.65	913.20	-31.69%	8,697.80	-1.48%	13.75
Sai Life Sciences Ltd. SAILIFE	1,395.00	81.97	29,652.69	0.00	73.29	21.22%	554.29	11.66%	20.97

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	439.21	279.72	395.56	439.78	579.51	496.42	537.47	556.46	602.14	554.29
Expenses	314.55	253.61	293.34	320.03	421.93	375.49	391.64	368.61	425.59	406.28
	124.66	26.12	102.22	119.75	157.57	120.93	145.83	187.85	176.55	148.00
	28.38%	9.34%	25.84%	27.23%	27.19%	24.36%	27.13%	33.76%	29.32%	26.70%
	3.34	8.11	9.95	9.12	9.60	9.90	15.33	0.09	15.81	3.54
Interest	20.89	21.22	20.93	23.13	10.89	12.36	9.35	9.70	7.83	7.64
	31.05	31.07	35.92	34.09	37.49	37.72	39.75	44.08	45.31	45.94
	76.05	-18.07	55.32	71.65	118.80	80.75	112.05	134.17	139.23	97.97
	26.20%	25.28%	24.97%	24.84%	25.70%	25.13%	25.17%	25.19%	25.13%	25.20%
	56.13	-13.50	41.51	53.85	88.27	60.46	83.84	100.38	104.24	73.29
	3.11	-0.74	2.20	2.59	4.24	2.90	4.00	4.75	4.92	3.45

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	869.79	1,217.14	1,467.39	1,696.45	2,195.12
	869.59	1,217.14	1,465.18	1,694.57	2,192.49
EXPENDITURE :
Increase/Decrease in Stock	-2.83	-4.59	22.43	4.97	-7.22
Raw Material Consumed	269.59	427.18	423.30	460.80	578.12
Power & Fuel Cost	31.86	43.73	49.49	48.19	64.63
Employee Cost	308.97	417.29	494.91	549.12	683.06
Other Manufacturing Expenses	71.94	86.92	88.46	95.71	132.45
General and Administration Expenses	46.85	57.85	73.64	80.38	114.75
Selling and Distribution Expenses	7.74	8.56	8.16	11.80	14.70
Miscellaneous Expenses	10.58	11.32	17.66	35.78	4.49
	744.71	1,048.24	1,178.04	1,286.73	1,584.97
Operating Profit (Excl OI)	124.89	168.90	287.14	407.84	607.52
	28.15	27.97	29.09	36.78	74.40
	153.03	196.86	316.23	444.62	681.93
Interest	53.18	81.02	87.56	78.34	40.88
PBDT	99.86	115.84	228.67	366.28	641.05
	90.16	99.43	119.44	138.57	166.86
Profit Before Taxation & Exceptional Items	9.70	16.41	109.23	227.70	474.19
Exceptional Income / Expenses					-8.00
	9.70	16.41	109.23	227.70	466.19
Provision for Tax	3.47	6.42	26.43	57.57	117.28
	6.23	9.99	82.81	170.13	348.91
Extra items				0.00	0.00
Consolidated Net Profit	6.23	9.99	82.81	170.13	348.91
Profit Balance B/F	456.09	464.09	469.56	553.42	724.50
Appropriations	462.32	474.07	552.37	723.55	1,073.41
	3.55	1.75	46.88	8.16	16.48
Adjusted EPS	0.35	0.18	4.69	8.16	16.48

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	17.94	18.01	18.05	20.84	21.18
Share Warrants & Outstandings	8.72	9.48	10.61	5.08	4.48
Total Reserves	851.90	860.61	946.48	2,102.43	2,458.03
Reserve excluding Revaluation Reserve	851.90	860.61	946.48	2,102.43	2,458.03
Revaluation reserve	0.00	0.00
	878.57	888.09	975.14	2,128.35	2,483.69
Secured Loans	297.17	260.97	277.25		20.50
Deferred Tax Assets / Liabilities	56.89	54.47	73.13	96.84	114.90
Other Long Term Liabilities	192.37	199.52	177.05	164.69	127.62
Long Term Provisions	18.93	16.68	66.18	60.10	58.63
Total Non-Current Liabilities	565.36	531.64	593.61	321.62	321.65
Trade Payables	199.21	208.95	138.47	322.51	285.34
Other Current Liabilities	102.84	167.37	218.76	262.62	407.02
Short Term Borrowings	404.06	371.97	374.30	128.64	69.62
Short Term Provisions	8.49	10.57	8.37	45.37	142.60
Total Current Liabilities	714.60	758.85	739.90	759.14	904.59
Total Liabilities	2,158.52	2,178.59	2,308.66	3,209.12	3,709.93
Gross Block	1,259.84	1,418.40	1,679.38	2,116.27	2,606.63
Less: Accumulated Depreciation	287.79	381.48	499.53	628.06	791.80
Net Block	972.05	1,036.92	1,179.84	1,488.21	1,814.83
Capital Work in Progress	188.69	151.00	106.90	124.46	270.45
Non Current Investments	0.02	1.87	1.87	1.94	3.51
Long Term Investment	0.02	1.87	1.87	1.94	3.51
Long Term Loans & Advances	49.98	23.62	73.85	62.62	90.91
Other Non Current Assets	2.42	1.22	1.09	0.73	48.78
Total Non-Current Assets	1,213.15	1,214.64	1,363.55	1,677.96	2,228.49
Currents Investments					46.99
Inventories	126.91	139.53	87.44	118.87	150.97
Sundry Debtors	242.90	284.05	256.18	354.78	373.62
Cash and Bank	130.29	86.34	158.80	463.88	110.87
Other Current Assets	24.32	52.15	50.50	58.82	70.93
Short Term Loans and Advances	420.95	401.88	392.19	534.81	728.05
Total Current Assets	945.38	963.95	945.11	1,531.16	1,481.44
Net Current Assets (Including Current Investments)	230.78	205.10	205.21	772.02	576.85
Total Assets	2,158.52	2,178.59	2,308.66	3,209.12	3,709.93
Contingent Liabilities	19.02	15.69	24.08	58.11	97.31
Total Debt	751.32	699.23	710.16	128.64	95.13
	495.25	498.34	545.86	101.88	117.07
Adjusted Book Value	49.52	49.83	54.59	101.88	117.07

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	9.70	16.41	109.23	227.70	466.19
Adjustment	127.84	172.15	205.97	239.07	155.66
Changes In working Capital	-24.55	34.93	-38.24	-131.09	-73.80
Cash Flow after changes in Working Capital	112.99	223.48	276.96	335.68	548.06
Cash Flow from Operating Activities	104.87	219.40	263.09	314.05	509.13
Cash Flow from Investing Activities	-103.71	-101.78	-192.38	-536.67	-395.41
Cash Flow from Financing Activitie	71.92	-200.65	-95.30	301.43	-123.68
Net Cash Inflow / Outflow	73.08	-83.03	-24.59	78.81	-9.96
Opening Cash & Cash Equivalents	40.63	115.78	35.53	11.97	91.05
Effect of Foreign Exchange Fluctuations	2.08	2.78	1.03	0.28	0.82
Closing Cash & Cash Equivalent	115.78	35.53	11.97	91.05	81.91

Ratios

Valuation

81.97

11.61

42.28

13.18

17.03

120.17

Profitability

15.16

20.97

10.09

27.68

15.89

Leverage & Liquidity

0.04

1.64

12.40

Returns

0.00

0.63

Shareholding Pattern

Numbers in percentages

Particulars	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26	Sep '26
	35.24	35.24	35.17	35.15	34.94	34.70	34.61	34.53	34.50
	13.24	23.67	25.62	36.22	52.41	52.81	52.71	52.36	52.23
	51.52	41.09	39.21	28.64	12.65	12.49	12.68	13.11	13.26
	64.76	64.76	64.83	64.85	65.06	65.30	65.39	65.47	65.50
No. of Shareholders	5,72,970	1,81,122	1,40,677	1,26,380	1,19,705	1,14,820	1,17,527	1,25,096	1,43,124

Mutual Funds Invested(176)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 112 active funds hold 28.82% in Sai Life Sciences Ltd., contributing to ₹9.33K Cr of holdings

Fund				As of
NI Nippon India Small Cap Fund - Growth - Direct PlanSmall cap Fund	1,000.66	1.24	65,63,832	Sep '26
IN Invesco India Smallcap Fund - Growth - Direct PlanSmall cap Fund	829.42	5.14	54,40,617	Sep '26
IN Invesco India Large & Mid Cap Fund - Growth - Direct PlanLarge & Mid Cap	653.07	5.36	42,83,799	Sep '26
NI Nippon India Multi Cap Fund - Growth - Direct PlanMulti Cap Fund	605.06	1.13	39,68,891	Sep '26
AX Axis Small Cap Fund - Growth - Direct PlanSmall cap Fund	564.37	1.84	37,02,004	Sep '26
IN Invesco India Midcap Fund - Growth - Direct PlanMid Cap Fund	520.91	3.31	34,16,927	Sep '26
HS HSBC Small Cap Fund - Growth - Direct PlanSmall cap Fund	408.49	2.21	26,79,487	Sep '26
NI Nippon India Pharma Fund - Growth - Direct PlanPharma & Health Care	359.13	3.92	23,55,745	Sep '26
DS DSP Healthcare Fund - Growth - Direct PlanPharma & Health Care	244.33	6.52	16,02,712	Sep '26
AB Aditya Birla Sun Life Small Cap Fund - Growth - Direct PlanSmall cap Fund	192.57	3.15	12,63,192	Sep '26

Corporate Actions

Showing: All

Date	Type	Details
2026-10-01	Board Meeting	Quarterly Results
2026-08-24	AGM
2026-07-01	Board Meeting	Quarterly Results

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Sai Life Sciences Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

8 members across the board and senior leadership

Runa Karan

Company Secretary & Compliance Officer

—

Ranga Raju Kanumuri

Chairman

₹3.16 Cr

Mar '26

Kanumuri Ranga Raju

Chairman

₹2.91 Cr

Mar '25

Krishnam Raju Kanumuri

Managing Director & Chief Executive Officer

₹13.08 Cr

Mar '26

Sivaramakrishnan Chittor

Whole Time Director & CFO

₹19.32 Cr

Mar '26

Suchita Sharma

Non Executive Independent Director

₹47.50 L

Mar '26

Ramesh Ganesh Iyer

Non Executive Independent Director

₹48.00 L

Mar '26

Dinesh V Patel

Non Executive Independent Director

₹47.99 L

Mar '26

SAILIFE Latest News

News

7 of 7 articles

EQUITY1 Oct 2026 · 14:23

Sai Life Sciences submits board meeting intimation

EQUITY17 Sept 2026 · 15:34

Sai Life Sciences informs about outcome of AGM

EQUITY1 Sept 2026 · 17:23

Sai Life Sciences informs about allotment of equity shares under ESOP

EQUITY21 May 2026 · 15:18

Sai Life Sciences informs about earnings call transcript

COMPANY15 May 2026 · 12:58

Sai Life Sciences reports 18% rise in Q4 consolidated net profit

The total consolidated income of the company increased by 4.85% at Rs 617.66 crore for Q4FY26

EQUITY14 May 2026 · 23:09

Sai Life Sciences reports Profit after tax of Rs 1025.32 Mln, in the March 2026 quarter

EQUITY11 May 2026 · 16:40

Sai Life Sciences informs about earnings conference call

SAILIFE

₹1,395.00

-0.07%